A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Prabhudev, Prema
- A Pilot Syudy of Relation of Polycystic Ovary Syndrome and Metabolic Disorder in Davangere, Karnataka
Authors
1 Department of Obstetrics and Gynaecology, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN
2 Department of Anatomy, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN
3 Department of Forensic Medicine & Toxicology, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN
4 Department of Surgical Oncology, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN
Source
Indian Journal of Public Health Research & Development, Vol 3, No 2 (2012), Pagination: 40-44Abstract
Introduction
Polycystic ovarian syndrome (PCOS) is seen in 5 - 10% of women of the reproductive age, is the most common form of anovulatory infertility.
Evidence prove that these women exhibit a characteristic dyslipidaemia non insulin dependent diabetes and cardiovascular disease in later life, which are the hallmarks of the metabolic syndrome.
Presence of 3 of 5 common cardiovascular risk factors as a criteria, the prevalence of metabolic syndrome in PCOS is very high (43 - 46%).
Primary infertility cases with clinical features of menstrual irregularities, weight gain, hirsutism, acne and galactorrhea with scan picture of polycystic ovaries were considered for diagnosing PCOS cases.
Aim of the Study
Aim is to establish the relation between PCOS and metabolic syndrome.
Material and Methods
Study Design
A prospective, noninterventional case control study was conducted with 60 primary infertility patients, attending the gynaecological department, S.S. Institute of Medical Sciences and Research Centre, Davangere, Karnataka.
Study population
All these patients had clinical features suggestive of PCOS, of these 30 patients with ultrasound findings of polycystic ovaries were taken as cases and the others were age matched contemporary controls.
Age group: 20 - 30 years. Duration of study: 8 months. (Dec. 2009 - July 2010)
Methodology
After a brief history, waist circumference and blood pressure was recorded, then patients were asked to come on overnight fasting for a fasting blood sugar level and lipid profile assessment.
Results
In the present study all the five parameters needed for diagnosing metabolic syndrome were raised in PCOS cases and compared to controls. Values were statistically significant by student's unpaired 't' test.
An incidence of 38% of metabolic syndrome was noted in the PCOS cases studied.
Conclusion
Women with PCOS were strongly associated with metabolic syndrome when compared with the controls.
Obesity, high triglycerides and low high density lipoprotein levels are closely linked to insulin resistance and they are independent predictors of myocardial infarction and cardiovascular disease.
Results strongly indicate the need for comprehensive screening and education program for women of all ages with PCOS. Modification of lifestyle factors such as diet and exercise along with insulin sensitizers and lipid lowering agents can prevent long term health risks.
References
- Hull MGR. Epidemilogy of infertility and polycystic ovarian disease : endocrinological and demographic studies. Gynecol Endocrinol 1987;1(235-45).
- Adams J, Polson DW, Franks S. Prevalenceof polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 1986;239:355-9.
- Frank S. Polycystic ovary syndroem. N Engl J Med 1995;333:853- 861.
- Glueck CJ, Papanna R, Wang P et al. Incidence and treatmetn of metabolic syndrome in newly referred women with confirmed polycystic ovary syndrome. Metabolism 2003;52:908-15.
- Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among us adults : findings from the third national health and trition examination survey. JAMA 2002;287:356-9.
- Attaran Marjan. Polycystic ovary syndrome, cleveland clinicmeded 2004;1-8.
- Conway G, Agarwal R, Betteridge DJ, Jacobs HS. Risk factors for coronary heart disease in lean and obese PCOS. Clin Endocrinol 1992;37:119-125.
- Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
- Faloia E, Canibus P, Gatti C, Frezza F, et al. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest 2004;27:424-9.
- Dahlgren E, Janson PO, Johansson S. Polycystic ovary syndrome and risk for myocardial infarction evaluated for a risk factor model based on a prospective study of women. Acta Obstet Gynecol Scand 1992;71:599-604.
- Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome : a prospective controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9.
- Gaziano JM, Hennekens CH, O’Donnell. Fasting triglycerides, high density lipoprotein and risk of myocardial infarction. Circulation 1997;96:2520-5.
- Maruyama C, Imamura K, Teramato T. Assessment of LDL particle size by triglyceride / HDL cholesterol ratio in nondiabetic heatlhy subjects. J Atheroscler Thromb 2003;10:186-91.
- McLaughlin T, Abbasi F, Cheal K, Chu J, et al. Use of metabolic markers identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:802-9.
- Brehm A, Pfeiler G, et al. Relationship between serum lipopotein ratios and insulin resistance in obesity. Clin Chem 2004;54:2316-22.
- Executive summary of the third report of the NECP, expert panel on detection, evaluation and treatment of high blood cholesterol in adults (ATP III). J Am Med Asso 2001;285:2486- 2497.
- Barnard RJ, Wen SJ. Exercise and diet in the prevention and control of the metabolic syndrome. Sports Med 1994;18:218- 28.
- Clinical Use and Safety of Medical Method of first Trimester Abortion
Authors
1 Department of Obstetrics and Gynaecology, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN
2 Department of Anatomy, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN
3 Department of Forensic Medicine & Toxicology, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN
4 Department of Surgical Oncology, S.S.Institute of Medical Sciences & Research Centre, Davangere-577005, Karnataka, IN
Source
Indian Journal of Public Health Research & Development, Vol 3, No 2 (2012), Pagination: 45-48Abstract
Introduction
Women have a right to undergo an abortion if she wishes. Medical abortion is legally accepted under the Indian law. Mifepristone and misoprostol combination offers a safe, nonsurgical alternative for pregnancy termination with good success rates.
Aims and Objectives
The purpose of this study was to evaluation of the clinical efficacy of the combination of mifepristone and misoprostol orally for early termination of pregnancy.
Methods
A prospective clinical study conducted during a one year period included 100 healthy pregnant women consenting for a legal abortion with an ammenorrhoea of no more than 63 days.
Results
This method had a success rate of 94%, with an average induction abortion interval between 40-50 hours, one women needed surgical curettage. No serious side effects expect for nausea was noted.
Conclusion
The combination of mifepristone and misoprostol is effective for the termination of early pregnancy in terms of success, tolerance, safety and practicality.
References
- Manju MV. Jassawalla MJ. Manual ontermination of pregnancy, 3rd edn., 1999;9-11,55-59.
- WHO : Pregnancy termination with mifepristone and semeprost – A multicentre comparison between repeated doses and a single dose of mifepristone; fertile steril; 1991:56:32-40.
- Norman JE, Kelly RW, Glasler AF. Effects of Mifepristone in vivo on decidual prostaglandin synthesis and metabolism; contraception; 1991;49:88-89.
- Usha K. Antiprogesterons, today and tomarrow, review article. J Obs Gynec 2000;26-34.
- Wel SG et al. Termination of early pregnancy by two regimens of mifepristone with misoprostol and PGO5 – a multicentre randomized clinical trial in china; Contraception; 1994;50:501- 510.
- Birgerson L, Odlind V. Early pregnancy termination with antiprogestins : a comparative clinical study of Ru 486 given in two dose regimens and epostane, Fertil Steril 1987;48(4):565- 70.
- Remi P, Elisabeth A et al. Early termination of pregnancy with mifepristone and the orally active prostaglandin misoprostol, N Engl J Med 1993;328:1509-13.
- Bahzad C, Wyssling H, Saraya, Yougen S. Termination of early human pregnancy with mifepristone and the prostaglandin analogue sulprostone; a multicentre randomized comparison between two treatment regimens; Oxford J Human Reprod 1989;4(6):718-725.
- Beatrice C, LeNelly S, Andre U et al. Termination of early pregnancy by the progesterone antagonist Ru (486) Mifepristone, N Engl J Med, 1996;315:1565-1570.
- UK Multicentre trial : The efficacy and tolerance of mifepristone and prostaglandin in first trimester termination of pregnancy, Br J Obstet Gynaecol; 1998;97:480-86.
- Florence D, Catherine D, Joelle B, Rene F. Efficacy of progesterone antagonist Ru 486 (Mifepristone) for preoperative cervical dilatation during first trimester abortion, Oxford J Human Reproduct 1988;3(5):583-84.